Fermentalg SA (ALGAE) AI Stock Analysis

• Market Cap: €43.98M
• Dividend Yield: N/A
• Average Volume (3M): 243.57K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.11
• Revenue Growth: 59.05%
• EPS Growth: 57.39%
• Country: FR
• Employees: 58
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.04
• Shares Outstanding: 89,844,100
• 10 Day Avg. Volume: 168,916
• 30 Day Avg. Volume: 243,571
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €0.50
• Price Target Upside: 0.00%
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 50 Neutral
• Price Target: €0.50 ▲(0.00% Upside)

Fermentalg SA's overall stock score is driven by strong revenue growth but is tempered by significant profitability challenges and a negative valuation due to ongoing losses. Technical analysis suggests a neutral to slightly positive outlook, but the lack of earnings call data and corporate events limits further insights.

Fermentalg SA Business Overview & Revenue Model

Company Description

Fermentalg SA develops, produces, and sells active ingredients extracted from microalgae for the food, health, nutrition, and environment sectors in France and internationally. It offers DHA ORIGINS, a plant-based DHA oil; KALVEA PLUS, a nutritious algal protein concentrate dedicated to aquafeed applications; Everzure, an extract of natural acid stable blue color; BLUE ORIGINS AOX, an antioxidant and anti-inflammatory activities; BLUE ORIGIN, a natural color; and environmental and clean air solutions that captures CO2 in industries. The company was incorporated in 2009 and is headquartered in Libourne, France.

How the Company Makes Money

Fermentalg generates revenue through multiple streams, primarily by selling its microalgae-derived products to various sectors. The company engages in direct sales of its omega-3 fatty acids and other ingredients to manufacturers in the food, dietary supplements, and cosmetic industries. Additionally, Fermentalg collaborates with strategic partners and companies to develop customized solutions tailored to specific market needs, which can lead to joint ventures or co-development agreements that further enhance its revenue. The company also benefits from research grants and subsidies aimed at promoting sustainable biotechnology and innovation, which support its R&D efforts and operational costs.

Fermentalg SA Financial Statement Overview

Summary

Fermentalg SA shows strong revenue growth but faces profitability challenges with significant net losses and negative margins. The balance sheet indicates moderate leverage and stable equity, while cash flow management has improved but remains negative.

Income Statement

The company has shown significant revenue growth, increasing from €4.06 million in 2023 to €11.50 million in 2024, reflecting a revenue growth rate of 183.45%. However, the company is not yet profitable, with a net loss of €12.88 million in 2024. Margins remain under pressure as evidenced by negative EBIT (-80.49%) and EBITDA (-86.87%) margins, indicating ongoing operational challenges.

Balance Sheet

The company maintains a positive equity position with a debt-to-equity ratio of 0.38, suggesting moderate leverage. However, total liabilities have increased, which may pose risks if revenue growth does not continue. The equity ratio stands at 64.02%, indicating a reasonable level of financial stability despite losses.

Cash Flow

The operating cash flow improved significantly from a deficit of €8.66 million in 2023 to a deficit of €0.53 million in 2024. Free cash flow remains negative at €-2.00 million, but the company has managed to reduce its free cash flow deficit. The operating cash flow to net income ratio improved, reflecting better cash management despite ongoing losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.06M	11.50M	4.06M	7.65M	5.65M	2.21M
Gross Profit	-2.62M	2.50M	536.00K	-828.00K	-675.00K	-1.25M
EBITDA	-11.21M	-9.99M	-9.78M	-7.61M	-6.97M	-8.02M
Net Income	-14.15M	-12.88M	-14.15M	-9.87M	-6.85M	-6.88M
Balance Sheet
Total Assets	50.24M	51.14M	50.24M	57.54M	60.88M	41.89M
Cash, Cash Equivalents and Short-Term Investments	11.16M	20.58M	11.16M	15.90M	26.01M	11.84M
Total Debt	15.35M	12.60M	15.35M	11.02M	9.61M	15.84M
Total Liabilities	19.40M	18.39M	19.40M	15.56M	13.87M	21.58M
Stockholders Equity	30.85M	32.76M	30.85M	41.98M	47.00M	20.30M
Cash Flow
Free Cash Flow	-11.18M	-2.00M	-11.18M	-13.72M	-12.55M	-11.70M
Operating Cash Flow	-8.69M	-531.00K	-8.69M	-8.24M	-7.66M	-8.57M
Investing Cash Flow	-1.76M	-1.13M	-1.76M	-7.29M	-4.75M	-2.05M
Financing Cash Flow	5.71M	11.08M	5.71M	5.42M	26.58M	14.44M

Fermentalg SA Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALGAE, the sentiment is Negative. The current price of 0.5 is below the 20-day moving average (MA) of 0.51, below the 50-day MA of 0.51, and above the 200-day MA of 0.45, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 43.01 is Neutral, neither overbought nor oversold. The STOCH value of 6.08 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALGAE.

Fermentalg SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ABNX	52 Neutral	€126.12M	-27.45	-59.27%	―	-10.91%	-25.57%
ALGAE	50 Neutral	€43.98M	―	-33.26%	―	59.05%	57.39%
ALVAL	46 Neutral	€18.78M	-1.25	-96.69%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%